UNITED STATES SECURITIES AND EXCHANGE COMMISSION October 17, 2016

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

PDL Biopharma, Inc.

File No. 000-19756 -CF#34093

PDL Biopharma, Inc. submitted an application under Rule 24b-2 requesting

confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 4, 2016.

Based on representations by PDL Biopharma, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.3	through November 4, 2025
Exhibit 10.4	through November 30, 2020
Exhibit 10.5	through August 4, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

> Brent J. Fields Secretary